Aytu BioPharma (NASDAQ:AYTU) Stock Passes Above 50-Day Moving Average – What’s Next?

Aytu BioPharma Inc. (NASDAQ:AYTU)’s share price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.19 and traded as high as $2.33. Aytu BioPharma shares last traded at $2.30, with a volume of 49,804 shares trading hands.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Zacks Research lowered shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 15th. Ascendiant Capital Markets boosted their price target on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $10.75.

Aytu BioPharma Stock Performance

The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27. The stock has a market cap of $25.32 million, a P/E ratio of -0.52 and a beta of 0.25. The stock has a fifty day simple moving average of $2.19 and a 200-day simple moving average of $2.38.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). The company had revenue of $12.41 million during the quarter, compared to the consensus estimate of $12.05 million. Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. Equities analysts expect that Aytu BioPharma Inc. will post -0.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aytu BioPharma

Hedge funds have recently bought and sold shares of the company. Daytona Street Capital LLC bought a new position in shares of Aytu BioPharma during the fourth quarter worth $26,000. Rothschild Wealth LLC acquired a new stake in Aytu BioPharma during the 4th quarter worth $52,000. BlackRock Inc. bought a new position in Aytu BioPharma during the second quarter worth about $49,000. Bellevue Asset Management LLC acquired a new position in Aytu BioPharma in the fourth quarter valued at about $65,000. Finally, XTX Topco Ltd bought a new stake in shares of Aytu BioPharma in the fourth quarter worth about $67,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.